Results for gilead

Add to feed Create your own feed

Latest

Gilead is launching a phase 1 clinical trial of an inhaled version of remdesivir, a drug used to treat Covid-19, that could be administered to patients outside of the hospital

tweet picture

Gilead Sciences, the maker of remdesivir, has announced the start of clinical trials for an inhaled version of the antiviral drug to treat Covid-19 patients who do not require hospitalization

Gilead testing inhaled form of Remdesivir that could be used to treat Covid-19 outside hospital By @leah_rosenbaum 

tweet picture

Gilead Sciences, the maker of remdesivir, has announced the start of clinical trials for an inhaled version of the antiviral drug to treat Covid-19 patients who do not require hospitalization

Gilead Sciences, the maker of remdesivir, has announced the start of clinical trials for an inhaled version of the antiviral drug to treat Covid-19 patients who do not require hospitalization

This is likely to be fast-tracked $GILD - Gilead launches early-stage study of inhaled remdesivir

Gilead begins testing inhalable form of remdisivir for COVID-19

tweet picture

#GileadSciences Inc said it has started an early-stage study of its antiviral #coronavirus  treatment.

Gilead begins testing inhalable form of remdisivir for COVID-19

tweet picture

Gilead’s shareholders want exorbitant profits from Remdesivir, even though it was the public that enabled its development.

Loading
Loading

Most relevant

As a company, Gilead is now worth over $15 billion more than before the pandemic, in part because it expects to make enormous profits by charging over $3,000 for a drug they had already developed years ago. Their greed must be stopped.

As Gilead charges $3,120 for its COVID drug, remdesivir, remember that the drug was developed with a $70,000,000 grant from the federal government paid for by American taxpayers. Once again, Big Pharma is set to profit on the people's dime.

Gilead's coronavirus treatment remdesivir to cost $3,120 per U.S. patient with private insurance

Remdesivir, a potential treatment for coronavirus, has boosted Gilead's stock price in recent days. But here's the catch: Remdesivir was developed with taxpayer funding through CDC and NIH. No drug that was developed with public dollars should be used to pad pharma profits.

Taxpayers provided funding for the development of this drug. Now Gilead is price-gouging off it during a pandemic. Beyond disgusting. Coronavirus treatment must be free to all.

As Gilead's stock price rises on reports of remdesivir, remember that the drug was developed with a $37.5 million grant from the federal government paid for by the taxpayers. Once again, Big Pharma is set to profit on the taxpayer's dime.

It is insane and unacceptable that the Trump Administration has given the Gilead pharmaceutical corporation a seven-year monopoly on a potential coronavirus treatment. We will not tolerate profiteering. Any treatment or vaccine must be made free for all.

NEW: Marc Short, the chief of staff to Vice President Pence, owns between $506,043 and $1.64 million worth of stocks in companies doing work linked to the Trump administration's pandemic response — including 3M, Abbott Labs and Gilead.

It's really incredible how sad Twitter can be. A credible hospital a credible reporter and a credible former FDA Commish are hopeful about Gilead's drug but almost every armchair doctor here is negative? Goodnight...

Great news today: My Administration just secured a historic donation of HIV prevention drugs from Gilead to help expand access to PrEP for the uninsured and those at risk. Will help us achieve our goal of ending the HIV epidemic in America!

Loading
Loading